• Innovation in Cachexia
    We are focused on bringing innovation to the treatment of cachexia and other muscle wasting conditions with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider.
  • Innovation in Cachexia
    We are focused on bringing innovation to the treatment of cachexia and other muscle wasting conditions with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider.
We are focused on bringing innovation to the treatment of cachexia and other muscle wasting conditions with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider.
NEWS
May 20, 2025
Actimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists
Read more>>>
Apr 24, 2025
Actimed Therapeutics Appoints Shaun Claydon as Chief Financial Officer
Read more>>>
Management Team
Robin Bhattacherjee

Robin Bhattacherjee

Chief Executive Officer
Fabio Dorigotti

Fabio Dorigotti

Chief Medical Officer
Shaun Claydon

Shaun Claydon

Chief Financial Officer
Elaine Morten

Elaine Morten

Head of Regulatory Affairs and Technical Development
Louise Bosworth

Louise Bosworth

Head of Clinical Operations

Pipeline